Munir Pirmohamed
Cited by
Cited by
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
M Pirmohamed, S James, S Meakin, C Green, AK Scott, TJ Walley, ...
Bmj 329 (7456), 15-19, 2004
Drug repurposing: progress, challenges and recommendations
S Pushpakom, F Iorio, PA Eyers, KJ Escott, S Hopper, A Wells, A Doig, ...
Nature reviews Drug discovery 18 (1), 41-58, 2019
Estimation of the warfarin dose with clinical and pharmacogenetic data
International Warfarin Pharmacogenetics Consortium
New England Journal of Medicine 360 (8), 753-764, 2009
Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance
RA Sharma, SA Euden, SL Platton, DN Cooke, A Shafayat, HR Hewitt, ...
Clinical cancer research 10 (20), 6847-6854, 2004
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ...
Nature genetics 41 (7), 816-819, 2009
Pharmacodynamic and Pharmacokinetic Study of Oral Curcuma Extract in Patients with Colorectal Cancer
RA Sharma, HR McLelland, KA Hill, CR Ireson, SA Euden, MM Manson, ...
Clinical Cancer Research 7 (7), 1894-1900, 2001
HLA-A* 3101 and carbamazepine-induced hypersensitivity reactions in Europeans
M McCormack, A Alfirevic, S Bourgeois, JJ Farrell, D Kasperavičiūtė, ...
New England Journal of Medicine 364 (12), 1134-1143, 2011
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes
EC Davies, CF Green, S Taylor, PR Williamson, DR Mottram, ...
PLoS one 4 (2), e4439, 2009
A randomized trial of genotype-guided dosing of warfarin
M Pirmohamed, G Burnside, N Eriksson, AL Jorgensen, CH Toh, ...
New England Journal of Medicine 369 (24), 2294-2303, 2013
Adverse drug reactions
M Pirmohamed, AM Breckenridge, NR Kitteringham, BK Park
Bmj 316 (7140), 1295-1298, 1998
Emergence and global spread of epidemic healthcare-associated Clostridium difficile
M He, F Miyajima, P Roberts, L Ellison, DJ Pickard, MJ Martin, TR Connor, ...
Nature genetics 45 (1), 109-113, 2013
Which drugs cause preventable admissions to hospital? A systematic review
RL Howard, AJ Avery, S Slavenburg, S Royal, G Pipe, P Lucassen, ...
British journal of clinical pharmacology 63 (2), 136-147, 2007
Active transport of imatinib into and out of cells: implications for drug resistance
J Thomas, L Wang, RE Clark, M Pirmohamed
Blood 104 (12), 3739-3745, 2004
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ...
Clinical Pharmacology & Therapeutics 90 (4), 625-629, 2011
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update
JA Johnson, KE Caudle, L Gong, M Whirl‐Carrillo, CM Stein, SA Scott, ...
Clinical Pharmacology & Therapeutics 102 (3), 397-404, 2017
The role of metabolic activation in drug-induced hepatotoxicity
BK Park, NR Kitteringham, JL Maggs, M Pirmohamed, DP Williams
Annu. Rev. Pharmacol. Toxicol. 45 (1), 177-202, 2005
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles
MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ...
Gastroenterology 141 (1), 338-347, 2011
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
T Eschenhagen, T Force, MS Ewer, GW De Keulenaer, TM Suter, ...
European journal of heart failure 13 (1), 1-10, 2011
Pharmacogenetics of warfarin: current status and future challenges
M Wadelius, M Pirmohamed
The pharmacogenomics journal 7 (2), 99-111, 2007
Genetic susceptibility to adverse drug reactions
M Pirmohamed, BK Park
Trends in pharmacological sciences 22 (6), 298-305, 2001
The system can't perform the operation now. Try again later.
Articles 1–20